Literature DB >> 20460920

Genetic and environmental susceptibility to non-alcoholic fatty liver disease.

Christopher Paul Day1.   

Abstract

While the majority of those with non-alcoholic fatty liver disease (NAFLD) will have simple hepatic steatosis, a minority will develop progressive steatohepatitis. Family studies and inter-ethnic variations in susceptibility suggest that genetic factors may be important in determining disease risk. Although no genetic associations with advanced NAFLD have been replicated in large studies, preliminary data suggest that polymorphisms in genes controlling lipid metabolism, pro-inflammatory cytokines, fibrotic mediators and oxidative stress may be associated with steatohepatitis and/or fibrosis. Recent whole genome-wide scans have identified genes contributing to inherited susceptibility to steatosis and it seems likely that similar approaches will identify genes associated with disease progression in the near future. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20460920     DOI: 10.1159/000282098

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  32 in total

1.  Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome.

Authors:  Luca Miele; Giovanni Gasbarrini; Valentina Giorgio; Antonio Gasbarrini; Antonio Grieco
Journal:  Intern Emerg Med       Date:  2015-11-24       Impact factor: 3.397

Review 2.  Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease.

Authors:  Tannaz Eslamparast; Sareh Eghtesad; Hossein Poustchi; Azita Hekmatdoost
Journal:  World J Hepatol       Date:  2015-02-27

Review 3.  Nonalcoholic fatty liver disease and polycystic ovary syndrome.

Authors:  Evangeline Vassilatou
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 4.  Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach.

Authors:  Anna Alisi; Ariel E Feldstein; Alberto Villani; Massimiliano Raponi; Valerio Nobili
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-01-17       Impact factor: 46.802

5.  Gut microbiota, fatty liver disease, and hepatocellular carcinoma.

Authors:  Huikuan Chu; Brandon Williams; Bernd Schnabl
Journal:  Liver Res       Date:  2018-02-21

Review 6.  Developmental programming of pediatric nonalcoholic fatty liver disease: redefining the"first hit".

Authors:  Michael S Stewart; Margaret J R Heerwagen; Jacob E Friedman
Journal:  Clin Obstet Gynecol       Date:  2013-09       Impact factor: 2.190

Review 7.  Insulin sensitizers for the treatment of non-alcoholic fatty liver disease.

Authors:  Zeynel Abidin Ozturk; Abdurrahman Kadayifci
Journal:  World J Hepatol       Date:  2014-04-27

8.  AdipoQ T45 G and G276 T Polymorphisms and Susceptibility to Nonalcoholic Fatty Liver Disease Among Asian Populations: A Meta-Analysis and Meta-Regression.

Authors:  Bai-Fang Wang; Ying Wang; Ran Ao; Jing Tong; Bing-Yuan Wang
Journal:  J Clin Lab Anal       Date:  2014-11-10       Impact factor: 2.352

Review 9.  MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease.

Authors:  Nadia Panera; Daniela Gnani; Annalisa Crudele; Sara Ceccarelli; Valerio Nobili; Anna Alisi
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

Review 10.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.